Table S1.
Baseline comorbidities and previous or concomitant osteoporosis treatments of patients with osteoporosis at high risk of fracture in Japan
| Characteristic | N=1,847 n (%) |
|---|---|
| Comorbidities | 893 (48.3) |
| Most frequently occurring comorbidities | |
| Hypertension | 306 (16.6) |
| Rheumatoid arthritis | 151 (8.2) |
| Hyperlipidemia | 140 (7.6) |
| Osteoarthritis | 105 (5.7) |
| Constipation | 97 (5.3) |
| Gastroesophageal reflux disease | 94 (5.1) |
| Insomnia | 86 (4.7) |
| Lumbar spinal canal stenosis | 83 (4.5) |
| Type 2 diabetes mellitus | 77 (4.2) |
| Gastritis | 66 (3.6) |
| Renal impairmenta | 404 (21.9) |
| Hepatic impairmentb | 217 (11.7) |
| Secondary osteoporosisc | 148 (8.0) |
| Glucocorticoid-induced osteoporosisc | 148 (8.0) |
| Past medical history | 598 (32.4) |
| Most frequently reported medical history | |
| Vertebral compression fracture | 58 (3.1) |
| Uterine leiomyoma | 51 (2.8) |
| Appendicitis | 41 (2.2) |
| Cerebral infarction | 35 (1.9) |
| Femoral neck fracture | 28 (1.5) |
| Gastric ulcer | 27 (1.5) |
| Hypertension | 25 (1.4) |
| Osteoarthritis | 22 (1.2) |
| Lumbar spinal canal stenosis | 21 (1.1) |
| Cataract | 21 (1.1) |
| History of drug therapy for osteoporosis | 1,101 (59.6) |
| Most common previous drug therapy for osteoporosis (used by ≥5 patients) | |
| Alendronate (oral) | 493 (26.7) |
| Alfacalcidol (oral) | 311 (16.8) |
| Risedronate (oral) | 266 (14.4) |
| Raloxifene (oral) | 190 (10.3) |
| Elcatonin (intramuscular) | 113 (6.1) |
| Minodronic acid (oral) | 89 (4.8) |
| Menatetrenone (oral) | 58 (3.1) |
| Calcitriol (oral) | 52 (2.8) |
| l-Aspartic acid (oral) | 34 (1.8) |
| Eldecalcitol (oral) | 18 (1.0) |
| Bazedoxifene (oral) | 15 (0.8) |
| Concomitant drug therapy for osteoporosis | 406 (22.0) |
| Most common concomitant drug therapy for osteoporosis (used by ≥5 patients) | |
| l-aspartic acid (oral) | 176 (9.5) |
| Alfacalcidol (oral) | 145 (7.9) |
| Menatetrenone (oral) | 101 (5.5) |
| Eldecalcitol (oral) | 39 (2.1) |
| Elcatonin (intramuscular) | 34 (1.8) |
| Raloxifene (oral) | 31 (1.7) |
| Risedronate (oral) | 28 (1.5) |
| Alendronate (oral) | 13 (0.7) |
| Minodronic acid (oral) | 10 (0.5) |
| Bazedoxifene (oral) | 7 (0.4) |
Notes:
a
Patients with renal impairment or chronic kidney disease stages 3 to 5 are defined as having renal impairment.
b
Patients with liver impairment or abnormal laboratory data regarding liver function (aspartate aminotransferase, alanine aminotransferase, and γ-glutamyl transpeptidase exceeded standard level) are defined as having hepatic impairment.
c
Information was not available on secondary osteoporosis for 328 patients or on glucocorticoid-induced osteoporosis for 337 patients.
Abbreviation: n, number.